Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer (NCT05386108)
An Open-label Multicenter Phase 1b-2 Study of Elacestrant in Combination With Abemaciclib in Women and Men With Brain Metastasis From Estrogen Receptor Positive, HER-2 Negative Breast Cancer
🩺 Plain-English Summary (8th-Grade Level)
This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER-2) negative breast cancer. Phase 1b was designed to select the recommended phase 2 dose (RP2D) and is followed by an ongoing phase 2 evaluation of elacestrant in combination with abemaciclib in participants with active brain metastases from ER-positive, HER-2 negative breast cancer.
Who can join: Review the eligibility criteria below.
Location: Providence Medical Foundation — Fullerton, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (86 Sites)
Showing the first 25 of 86 sites.
- Providence Medical Foundation — Fullerton, California
- California Research Institute — Los Angeles, California
- Carle Cancer Center — Urbana, Illinois
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Henry Ford Hospital — Detroit, Michigan
- Miami Valley Hospital South — Centerville, Ohio
- Oregon Health & Science University — Portland, Oregon
- SCRI Oncology Partners — Nashville, Tennessee
- University of Texas MD Anderson Cancer Center — Houston, Texas
- UT Health San Antonio University of Texas — San Antonio, Texas
- Virginia Cancer Institute — Norfolk, Virginia
- Antwerp University Hospital — Edegem,
- Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg — Leuven,
- Universite Catholique de Louvain (UCL) - Cliniques Universitaires Saint-Luc — Woluwe-Saint-Lambert,
- Institut de Cancerologie de l'Ouest site Paul Papin — Angers,
- Hôpital Morvan - CHRU de Brest - cancérologie et d'hématologie — Brest,
- Centre Francois Baclesse - Oncologie Medicale - Cancerolo — Caen,
- Centre Jean Perrin — Clermont-Ferrand,
- Centre Léon Bérard - Département Oncologie Médicale — Lyon,
- Centre de Cancerologie du Grand Montpellier — Montpellier,
- Hôpital de la Pitiê Salpêtriêre — Paris,
- Centre Hospitalier Universitaire de Poitiers — Poitiers,
- Institut Claudius Regaud — Toulouse,
- Klinikum Bayreuth GmbH — Bayreuth,
- Uniklinik Koeln - Klinik und Poliklinik fuer Frauenheilkunde — Cologne,
📞 Contact the Study Coordinator
Phone: (877) 332-7961
Email: clinicaltrials@menarinistemline.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Neoplasms
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) — Birmingham, Alabama
- (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer — Phoenix, Arizona
- Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer — Dallas, Texas
- Assessment of Quality of Life and Treatment Times for Patients With Invasive Type Breast Cancer in Martinique — Fort-de-France,
- Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer — Springdale, Arkansas
- The IDEA Study (Individualized Decisions for Endocrine Therapy Alone) — Stanford, California
Explore by condition: All Breast Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.